Aurobindo Pharma gets USFDA nod for generic cancer drug Bortezomib

“Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma (cancer of plasma cells) and is also used to treat adult patients with mantle cell lymphoma (cancer of lymph nodes), the company said.
New Delhi, Aurobindo Pharma said its wholly owned arm Eugia Pharma Specialities Ltd has received final approval from the US health regulator to manufacture and market its generic version of Bortezomib for injection used to treat certain types of cancer. The approval by the US Food and Drug Administration (USFDA) is for single-dose vial of Bortezomib for injection of strength 3.5 mg/vial, Aurobindo Pharma said in a regulatory filing. The product is the generic version of reference listed drug Velcade of Takeda Pharmaceuticals USA Inc.
The product is being launched immediately, it added.
Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma (cancer of plasma cells) and is also used to treat adult patients with mantle cell lymphoma (cancer of lymph nodes), the company said.
Source: HealthWorld